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Adolescentsa b s t r a c t
Until recently, all seasonal influenza vaccines have been trivalent, containing strains A(H1N1), A(H3N2),
and one of the two B strain lineages (Yamagata or Victoria), resulting in frequent mismatches between
the circulating B strain lineage and that included in the vaccine. A quadrivalent, inactivated, split-
virion influenza vaccine (IIV4) containing strains from both B lineages has been developed to address this.
We performed an open-label phase III study to assess the immunogenicity and safety of the 2013–2014
Northern Hemisphere formulation of IIV4 in children and adolescents 9–17 years of age in Taiwan.
Participants were vaccinated with one dose of IIV4 by intramuscular or deep subcutaneous injection.
Hemagglutinin inhibition (HAI) titers were measured before and 21 days after vaccination. Solicited
injection-site and systemic reactions were assessed for up to 7 days after vaccination, and adverse events
(AEs) were recorded until day 21. One hundred participants were included. Despite relatively high pre-
vaccination titers, post-vaccination HAI titers increased for all four strains, with geometric mean ratios
(day 21/day 0) of 2.29 for A(H1N1), 2.05 for A(H3N2), 3.33 for B/Massachusetts (Yamagata lineage),
and 4.59 for B/Brisbane (Victoria lineage). Post-vaccination seroprotection rates were 99% for A(H3N2)
and 100% for A(H1N1), B/Massachusetts, and B/Brisbane. Due to high pre-vaccination titers, rates of sero-
conversion/significant increase of HAI titer were relatively low at 24% for A(H1N1), 20% for A(H3N2), 39%
for B/Massachusetts, and 48% for B/Brisbane. Injection-site pain (56%), myalgia (45%), and malaise (15%)
were the most frequently reported solicited reactions, and most solicited reactions were mild or moder-
ate. No treatment-related AEs, immediate unsolicited AEs, unsolicited non-serious injection-site AEs,
grade 3 unsolicited AEs, or serious AEs were reported. In conclusion, this study showed that the 2013–
2014 Northern Hemisphere formulation of the intramuscular IIV4 was immunogenic and well tolerated
by children and adolescents 9–17 years of age.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Since the 1980s, two distinct genetic lineages of influenza B
virus, Victoria and Yamagata, have been co-circulating worldwide[1,2]. Both B lineages cause similar influenza illnesses. Until
recently, all vaccines for seasonal influenza were trivalent and con-
tained two A strains (H1N1, and H3N2) and one B strain lineage.
This has resulted in frequent mismatches between the circulating
B virus and that included in the vaccine, reducing vaccine effective-
ness. For example, in half of the Northern hemisphere influenza
seasons between 1999/2000 and 2012/2012, the B strain included
in the trivalent vaccine was not the same lineage as the dominant
circulating B strain [3].
Quadrivalent influenza vaccines containing both B lineages
have been developed and should help address the problem of B
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inactivated, split-virion influenza vaccine (IIV4)2 containing 15 lg
of hemagglutinin from the A(H1N1) and A(H3N2) strains, and B
strains from both lineages. Phase III clinical trials comparing IIV4
and the inactivated trivalent influenza vaccine (IIV3; Vaxigrip,
Sanofi Pasteur) have been completed in French and German adults
[6], in children 3–8 years of age in Poland, Finland, Mexico, and Tai-
wan (EudraCT No. 2011-005101-79; unpublished observations), and
in children/adolescents 9–17 years of age and adults 18–60 years of
age in the Asia-Pacific area [7]. These studies showed that the
immunogenicity of IIV4 was non-inferior to IIV3 for the three com-
mon strains and superior for the additional B strain. The studies also
showed similar safety profiles for IIV4 and the trivalent comparator.
To comply with registration requirements in Taiwan, we per-
formed a phase III study assessing the immunogenicity and safety
of the 2013–2014 Northern Hemisphere formulation of IIV4 in
children and adolescents 9–17 years of age.2. Material and methods
2.1. Study design
This was a phase III open-label, uncontrolled trial conducted at
National Taiwan University Hospital (Taipei, Taiwan R.O.C.) and
Chang Gung Children’s Hospital (Taoyuan, Taiwan R.O.C.) (WHO
Universal Trial No. U1111-1127-7693). The objectives were to
describe the immunogenicity and safety of the IIV4 2013–2014
Northern Hemisphere seasonal formulation in children and adoles-
cents. The study was approved by the institutions’ ethics commit-
tees and was conducted in compliance with International
Conference on Harmonisation guidelines for Good Clinical Practice
and the Declaration of Helsinki. Written informed consent was
obtained from parents or legal guardians before inclusion of partic-
ipants in the study.2.2. Study participants
Participants had to be 9–17 years of age. Girls could not be
pregnant or lactating and could not be of childbearing potential
or had to be using an effective method of birth control if sexually
active. Participants were excluded for the following reasons:
receipt of any vaccine in the 4 weeks preceding the trial vaccina-
tion or planned receipt of any vaccine in the 3 weeks following
receipt of the trial vaccine; vaccination against influenza in the
previous 12 months if administered in the context of a clinical trial
or in the previous 6 months if administered in the context of an
influenza vaccination campaign; receipt of immune globulins,
blood, or blood-derived products in the past 3 months; known or
suspected congenital or acquired immunodeficiency; receipt of
immunosuppressive therapy, such as anti-cancer chemotherapy
or radiation therapy, within the preceding 6 months; long-term
systemic corticosteroid therapy (prednisone or equivalent for more
than 2 consecutive weeks within the past 3 months); self-reported
history of seropositivity for human immunodeficiency virus, hep-
atitis B virus, or hepatitis C virus; hypersensitivity to any of the
vaccine components or history of a life-threatening reaction to
the vaccine used in the study or to a vaccine containing any of
the same substances; known or suspected thrombocytopenia;
bleeding disorder or receipt of anticoagulants in the 3 weeks pre-
ceding inclusion; alcohol abuse or drug addiction; chronic illness
that was at a stage where it might interfere with trial conduct or2 AE, adverse event; CI, confidence interval; GMT, geometric mean titer; GMTR
geometric mean ratio of the day 21 vs. day 0 titer; HAI, hemagglutination inhibition
IIV3, inactivated trivalent influenza vaccine; IIV4, inactivated tetravalent influenza
vaccine; SAE, serious adverse event.,
;completion; or moderate or severe acute illness or infection on the
day of vaccination or febrile illness (temperature P38.0 C)
2.3. Vaccine
IIV4 was a quadrivalent split virion, inactivated influenza vac-
cine and was produced by Sanofi Pasteur (Lyon, France). Each
0.5-ml dose was provided in a prefilled syringe and contained
15 lg of each hemagglutinin for the A/California/7/2009 (H1N1)
pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/2/2012 (Yama-
gata lineage), and B/Brisbane/60/2008 (Victoria lineage) strains.
2.4. Study conduct
All participants were vaccinated with one dose (0.5 ml) of IIV4
by the intramuscular or deep subcutaneous route. All subjects pro-
vided a pre-vaccination baseline blood sample (5 ml) and a second
blood sample (5 ml) at day 21 ± 3.
2.5. Immunogenicity endpoints
Immunogenicity endpoints were as defined by the Committee
for Medicinal Products for Human Use Note for Guidance CPMP/
BWP/214/96 and, as described previously [6,7], included geometric
mean titers (GMTs), geometric mean of individual titer ratio of
post-vaccination (day 21) vs. pre-vaccination (day 0) (GMTRs),
detectable hemagglutination inhibition (HAI) titer (P10), seropro-
tection (HAI titer P40), and seroconversion or significant increase
in HAI titer. Seroconversion was defined as a HAI titer <10 on day 0
and a HAI titerP40 on day 21, and significant increase was defined
as a HAI titerP10 on day 0 and aP4-fold increase in HAI titer on
day 21. HAI titers were measured as described previously [6] at
Focus Diagnostics, Inc. (Cypress, CA). Briefly, the highest serum
dilution resulting in complete inhibition of hemagglutination was
determined in two independent assay runs for each sample. The
titer for each sample was calculated as the geometric mean of
the reciprocal of the duplicate values. The lower limit of quantita-
tion was set at the reciprocal of the lowest dilution used in the
assay (10), and the upper limit of quantitation as the highest dilu-
tion used in the assay (10,240).
2.6. Safety endpoints
Subject, parents, or guardians recorded the daily temperature
and the presence and intensity grade of solicited injection-site
reactions (pain, erythema, swelling, induration, and ecchymosis)
and systemic reactions (fever, headache, malaise, myalgia, and
shivering) up to day 7 on diary cards. For children 9–11 years of
age, erythema, swelling, induration, and ecchymosis were consid-
ered grade 1 for >0 to <25 mm, grade 2 for 25 to <50 mm, and grade
3 for P50 mm; and in children and adolescents 12–17 years, they
were considered grade 1 for 25 to 650 mm, grade 2 for 51 to
6100 mm, and grade 3 for >100 mm. Fever was considered grade
1 for 38.0–38.4 C, grade 2 for 38.5–38.9 C, and grade 3 for
P39 C. Injection-site pain, headache, malaise, myalgia, and shiv-
ering were considered grade 1 for easily tolerated or no interfer-
ence with daily activity, grade 2 for sufficiently discomforting to
interfere with normal behavior or daily activities, and grade 3 for
significant, prevents normal daily activities.
Participants were followed-up by investigators for unsolicited
adverse events (AEs) until day 21 ± 3 according to International
Conference on Harmonisation E2A Guideline for Clinical Safety
Data Management: Definitions and Standards for Expedited
Reporting. AEs were coded using MedDRA version 14 (MedDRA
MSSO, McLean, VA, USA). Unsolicited AEs were considered grade
1 for no interference with activity, grade 2 for some interference
50 C.-Y. Lu et al. / Trials in Vaccinology 5 (2016) 48–52with activity, and grade 3 for significant, prevents daily activity.
Investigators also recorded whether the AEs were not related or
were possibly or definitely related to the treatment. Immediate
unsolicited AEs were those occurring within 30 min of vaccination.
AEs of special interest included anaphylaxis, Guillain–Barré syn-
drome, encephalitis/myelitis, neuritis, febrile and non-febrile con-
vulsions, thrombocytopenia, and vasculitis.
2.7. Statistical analysis
All statistical analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA). An estimate of study size was not
performed because this was a not a controlled study. Immuno-
genicity endpoints were analyzed within the immunogenicity
analysis set, which was defined as all subjects who received one
dose of the study vaccine and had pre- and post-vaccination titers
available. Missing or incomplete data were not replaced, with the
exception that all HAI titers under the lower limit of quantitation
(10) were assigned a value of 5 and all HAI titers above the upper
limit of quantitation (10,240) were assigned a value of 10,240. To
calculate GMTs, the means and 95% confidence intervals (CIs)
were determined from log10-transformed data using Student’s
t-distribution with n  1 degrees of freedom, after which antilog
transformations were applied to the results of calculations. Safety
endpoints were analyzed in the safety analysis set, defined as all
subjects who received the study vaccine. Missing safety data were
not replaced and no search for outliers was performed. CIs for sin-
gle proportions were calculated by the Clopper–Pearson method.
3. Results
3.1. Participants
One hundred children and adolescents 9–17 years of age (50
subjects at each site) were enrolled between 18 October 2013
and 19 November 2013. The trial was completed on 10 December
2013. All participants received a single dose of vaccine according to
protocol, completed the study, and provided full immunogenicity
results. All participants were Asian, 54% were male, and the mean
age was 13.4 ± 2.9 years. Approximately one-third (35%) of the par-
ticipants were between 9 and 11 years of age, and the remainder
was between 12 and 17 years of age. Nearly half (48%) had received
the previous year’s (2012–2013) influenza vaccine, 13% reported
receiving the 2011–2012 vaccine, 22% the 2010–2011 vaccine,
and 14% the 2009–2010 vaccine.
3.2. Immunogenicity
Baseline pre-vaccination HAI GMTs were relatively high at 257
for A(H1N1), 382 for A(H3N2), 497 for B/Massachusetts, 186 forTable 1
HAI antibody responses for each vaccine antigen.
A(H1N1)
Measure Time N = 100
GMT Day 0 257 (204, 324)
Day 21 589 (498, 697)
GMTRa Day 21/day 0 2.29 (1.93, 2.71
Seroprotectionb,% Day 0 95.0 (88.7, 98.4
Day 21 100.0 (96.4, 100
Seroconversion or significant increasec ,% Day 21 24.0 (16.0, 33.6
Values are for the immunogenicity analysis set, with the 95% CIs in brackets.
a GMTR defined as geometric mean of individual day 21/day 0 HAI titer ratios.
b Seroprotection defined as HAI titerP 40.
c Seroconversion defined as a HAI titer < 10 on day 0 and titerP 40 on day 21 and sign
vs. day 0.B/Brisbane (Table 1). Accordingly, baseline seroprotection rates
were also high (95.0% for A(H1N1), 97.0% for A(H3N2), 94.0% for
B/Massachusetts (Yamagata lineage), and 85.0% for B/Brisbane
(Victoria lineage).
Despite the relatively high baseline titers, vaccination increased
HAI GMTs for all four strains. Post-vaccination (day 21) HAI GMTs
were 589 for A(H1N1), 782 for A(H3N2), 1654 for B/Massachusetts,
and 856 for B/Brisbane. GMTRs (day 21/day 0) were between 2.05
and 4.59 for the four vaccine strains, and post-vaccination seropro-
tection rates were between 99% and 100%. Due to the high baseline
HAI titers, rates of seroconversion/significant increase were below
50% for all four strains (24.0% for A(H1N1), 20.0% for A(H3N2),
39.0% for B/Massachusetts, and 48.0% for B/Brisbane).3.3. Influence of previous seasonal influenza vaccination
Pre- (day 0) and post-vaccination (day 21) GMTs and day 21 vs.
day 0 GMTRs were similar between participants who were or were
not previously vaccinated for seasonal influenza, although there
was a non-significant trend for the GMTRs to be higher in partici-
pants who had not been previously vaccinated (Table 2). Likewise,
there was a non-significant trend for seroconversion/significant
increase rates to be higher in participants who had not been previ-
ously vaccinated for seasonal influenza.3.4. Solicited reactions
Solicited injection-site reactions were reported by 57% of partic-
ipants, and solicited systemic reactions were reported by 48%
(Table 3). Pain was the most frequently reported injection-site
reaction (56% of participants). All other injection-site reactions
were reported by 66% of participants (erythema, 6%; swelling
4%; induration, 2%; ecchymosis, 1%). Myalgia was the most fre-
quently reported systemic reaction (45% of participants), followed
by malaise (15%). Headache was reported by 8% and shivering by
3%. Fever was not reported for any participant. Except for one
report of severe (grade 3) malaise and one of severe myalgia, both
reported by the same participant and both of which resolved
within 1 day, solicited injection-site and systemic reactions were
all mild (grade 1) or moderate (grade 2).3.5. Unsolicited AEs
A total of 20 unsolicited non-serious systemic AEs were
reported by 17 participants. The most frequently reported
unsolicited AEs were nasopharyngitis (10% of participants),
diarrhea (2% of participants), and cough (2% of participants). None
of the unsolicited AEs was considered related to the vaccination.
Also, no immediate unsolicited AEs, unsolicited non-seriousA(H3N2) B/Massachusetts B/Brisbane
N = 100 N = 100 N = 100
382 (301, 484) 497 (366, 674) 186 (139, 250)
782 (649, 944) 1654 (1352, 2024) 856 (702, 1045)
) 2.05 (1.76, 2.39) 3.33 (2.57, 4.31) 4.59 (3.63, 5.81)
) 97.0 (91.5, 99.4) 94.0 (87.4, 97.8) 85.0 (76.5, 91.4)
.0) 99.0 (94.6, 100.0) 100.0 (96.4, 100.0) 100.0 (96.4, 100.0)
) 20.0 (12.7, 29.2) 39.0 (29.4, 49.3) 48.0 (37.9, 58.2)
ificant increase defined as a HAI titerP 10 on day 0 andP4-fold increase on day 21
Table 2
HAI antibody responses for each vaccine antigen by previous vaccination status.
Measure Vaccinated the previous
year for seasonal influenzaa
A/H1N1 A/H3N2 B/Massachusetts B/Brisbane
N = 100 N = 100 N = 100 N = 100
Day 0 GMT No 219 (160, 300) 371 (259, 529) 383 (245, 600) 172 (115, 257)
Yes 306 (217, 433) 395 (286, 544) 659 (437, 994) 203 (130, 318)
Day 21 GMT No 611 (477, 782) 881 (682, 1139) 1638 (1194, 2246) 881 (660, 1176)
Yes 566 (447, 716) 688 (520, 911) 1672 (1293, 2162) 830 (626, 1101)
Day 0/day 21 GMTRb No 2.79 (2.14, 3.64) 2.38 (1.90, 2.98) 4.28 (2.81, 6.50) 5.12 (3.70, 7.07)
Yes 1.85 (1.52, 2.25) 1.74 (1.42, 2.15) 2.54 (1.91, 3.38) 4.09 (2.88, 5.80)
Seroprotection at day 21c No 100.0 (93.2, 100.0) 98.1 (89.7, 100.0) 100.0 (93.2, 100.0) 100.0 (93.2, 100.0)
Yes 100.0 (92.6, 100.0) 100.0 (92.6, 100.0) 100.0 (92.6, 100.0) 100.0 (92.6, 100.0)
Seroconversion or significant increased, % No 32.7 (20.3, 47.1) 25.0 (14.0, 38.9) 50.0 (35.8, 64.2) 53.8 (39.5, 67.8)
Yes 14.6 (6.1, 27.8) 14.6 (6.1, 27.8) 27.1 (15.3, 41.8) 41.7 (27.6, 56.8)
Values are for the immunogenicity analysis set, with the 95% CIs in brackets.
a 48 of the 100 participants had been vaccinated the previous year for seasonal influenza. The remaining 52 had not been vaccinated the previous year.
b GMTR defined as geometric mean of individual day 21/day 0 HAI titer ratios.
c Seroprotection defined as HAI titerP 40.
d Seroconversion defined as a HAI titer < 10 on day 0 and titerP 40 on day 21 and significant increase defined as a HAI titerP 10 on day 0 andP4-fold increase on day 21
vs. day 0.
Table 3
Number and percentage of subjects reporting solicited reactions.
Solicited reaction Any Grade 3
Injection-site 57 (57.0) 0 (0.0)
Pain 56 (56.0) 0 (0.0)
Erythema 6 (6.0) 0 (0.0)
Swelling 4 (4.0) 0 (0.0)
Induration 2 (2.0) 0 (0.0)
Ecchymosis 1 (1.0) 0 (0.0)
Systemic 48 (48.0) 1 (1.0)
Fever 0 (0.0) 0 (0.0)
Headache 8 (8.0) 0 (0.0)
Malaise 15 (15.0) 1 (1.0)
Myalgia 45 (45.0) 1 (1.0)
Shivering 3 (3.0) 0 (0.0)
Values are for the safety analysis set (N = 100) and are the number of subjects
reporting the reaction, with the percentage in brackets.
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discontinuation were reported.4. Discussion
This study showed that the 2013–2014 Northern Hemisphere
formulation of the IIV4 was immunogenic and well tolerated by
children and adolescents 9–17 years of age in Taiwan. Despite high
baseline HAI titers against all four vaccine strains, an immune
response was induced by vaccination with IIV4. At day 21, after
vaccination, all but one subject was seroprotected against all four
vaccine strains.
In this study, rates of seroconversion/significant increase in titer
were 24% for A(H1N1), 20% for A(H3N2), 39% for B/Massachusetts,
and 48% for B/Brisbane. These rates are lower than in the phase III
trial in the Asia-Pacific area, which reported rates of 62–85% in this
same age group and 59–67% in adults [7]. The relatively low values
in this study were due to high baseline HAI titers against all strains
in this formulation of IIV4, especially for the two new strains in the
2013–2014 vaccine formulation (A/Texas/50/2012 (H3N2) and
B/Massachusetts/2/2012). The high baseline titers in this study may
have been due, in part, to cross-reactivity with strains in previous
influenza vaccines; however, in the 48 participants, not previously
vaccinated for seasonal influenza, at least 92% had detectable HAI
titers at baseline for all strains. Also, baseline titers were only
slightly higher in participants who were previously vaccinatedfor influenza than in those who were not. Thus, the high baseline
titers were probably mostly due to natural exposure to the same
or similar strains to those in this formulation IIV4.
Seroprotection, defined as a HAI titer of at least 1:40, was
attained by all subjects 21 days after vaccination. This cut-off is
commonly used as correlate of protection in adults, but appropri-
ate cut-offs have not been defined for children and adolescents
[8,9]. Much higher HAI titers (1:110) were needed to attain clinical
protection against influenza A(H3N2) in vaccine-naïve healthy
children 6 months to 6 years of age vaccinated with an adjuvanted
vaccine or a trivalent inactivated influenza vaccine [10]. Whether
this also applies to the vaccines tested and the population included
in this study is not clear. In addition, some authors have suggested
that serologic results overestimate the efficacy of inactivated influ-
enza vaccines, bringing into the question the use of a fixed cut-offs
as surrogates for protection [11,12], but alternatives have not been
validated, so for the current study, we used the standard defini-
tions of serologic response requested by the Taiwanese authorities.
As reported in the previous phase III study in the Asia-Pacific
region [7], IIV4 was well tolerated. In both studies, 57% of partici-
pants 9–17 years of age reported solicited injection-site reactions
within 7 days of vaccination. In both studies, the most frequent
solicited reaction was injection-site pain. Solicited systemic reac-
tions were reported by 48% of participants in the current study
and 44% in the Asia-Pacific study. Furthermore, in the current
study, fever was not reported and only two grade 3 solicited reac-
tions (myalgia and malaise) were reported, both of which resolved
within 1 day. There were also no reports of grade 3 unsolicited AEs,
treatment-related unsolicited AEs, immediate AEs, SAEs, or discon-
tinuation of the study due to an AE.
5. Conclusion
This study showed that despite high baseline HAI titers, the
2013–2014 Northern Hemisphere formulation of the IIV4 was
immunogenic in children and adolescents 9–17 years of age. The
study also showed that the IIV4 was well tolerated.
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